IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported the successful 12-month safety results of the Company’s “Mercury 1” Phase 3 registration trial for its fixed-dose combination product candidate, Roclatan™. Mercury 1 is a 12-month safety and efficacy tria
Category: Business
Global Retinal Drugs Market to Grow at a CAGR of 11.6% by 2021 – Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis & Regeneron – Research and Markets
DUBLIN–(BUSINESS WIRE)–The “Global Retinal Drugs Market 2017-2021” report has been added to Research and Markets’ offering. The global retinal drugs market to grow at a CAGR of 11.66% during the period 2017-2021. The report, Global Retinal Drugs Mark…
LSGPA Invests an Additional $500,000 in MacuLogix, Inc.
HARRISBURG, Pa.–(BUSINESS WIRE)–#AMD–The Life Sciences Greenhouse of Central Pennsylvania (LSGPA) announced today an additional investment of $500,000 in MacuLogix, Inc. The investment was part of a syndicate with other, unnamed investors and brings LSGPA’s total investment in the Middletown-based firm to over $2 million. MacuLogix is the developer of the AdaptDx, an automated dark adaptometer that enables eye care professionals to diagnose, monitor and treat age-related macular degeneration (AMD)
Global Cosmetic Contact Lenses Market 2017-2021 – Key vendors are The Cooper Companies, Johnson & Johnson, Novartis & Valeant – Research and Markets
DUBLIN–(BUSINESS WIRE)–The “Global Cosmetic Contact Lenses Market 2017-2021” report has been added to Research and Markets’ offering. The analysts forecast the global cosmetic contact lens market to grow at a CAGR of 4.96% during the period 2017-2021…
Visioneering Technologies, Inc. Appoints Gary Sacks as Executive Territory Manager For New York/Western Massachusetts
ATLANTA–(BUSINESS WIRE)–Gary Sacks has joined Visioneering Technologies, Inc., as Executive Territory Manager, New York/Western Massachusetts
Castle Biosciences’ Uveal Melanoma Test Receives Positive Medicare Local Coverage Determination and Commercial Insurance Positive Coverage Policies
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced three important milestones in improving access to DecisionDx®-UM, the standard of care prognostic tool for patients with uveal melanoma (UM), an aggressive form of eye cancer. Palmetto GBA, the administrator of the MolDX® program that assesses molecular diagnostic technologies on behalf of the Centers for Medicare and Medicaid Services (CMS),
BioTime to Host Key Opinion Leader Event on the Topic of Dry AMD in New York City
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced today that it will host a Key Opinion Leader event on the topic …
Global Tipiracil / Trifluridine Sales, Price Analysis, & Sales Forecasts 2016-2021 – Research and Markets
DUBLIN–(BUSINESS WIRE)–The “Tipiracil / Trifluridine Sales, Price Analysis, & Sales Forecast – 2017” report has been added to Research and Markets’ offering. Find out the sales of Tipiracil / Trifluridine worldwide and by countries in North America, Europe, Japan, BRIC, and Australia. Discover the growth trends of Tipiracil / Trifluridine by countries, and also find out sales forecast until 2021. The research also provides Tipiracil / Trifluridine unit price by countries. The sales and pr
Nightstar Appoints David Lubner to its Board of Directors
BOSTON & LONDON–(BUSINESS WIRE)–Nightstar Appoints David Lubner to its Board of Directors
Top 3 Emerging Trends Impacting the Global Intraocular Lens Market From 2017-2021: Technavio
LONDON–(BUSINESS WIRE)–#MedicalDevices–Technavio’s report on the global intraocular lens market provides an analysis of the most important trends expected to impact the market outlook.
Visioneering Technologies, Inc. Appoints Michelle Kirst as Territory Manager for New Jersey
ATLANTA–(BUSINESS WIRE)–Visioneering Technologies, Inc., welcomes Michelle Kirst as Territory Manager for New Jersey.
Beaver-Visitec International Acquires Vitreq
WALTHAM, Mass.–(BUSINESS WIRE)–Beaver-Visitec International (BVI), a leading global developer, manufacturer, and marketer of specialized surgical devices for the ophthalmic marketplace, announced today it has acquired Vitreq, a next-generation ophthalmic technology company. Additional terms of the transaction were not disclosed. “At Vitreq, it’s our mission to develop reliable, safe, and sophisticated tools that provide surgeons with the support and innovation necessary to perform at the high
Ocular Therapeutix™ Receives Complete Response Letter from FDA for DEXTENZA™ NDA
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular TherapeutixTM, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA), regarding its resubmission of a New Drug Application (NDA) for DEXTENZA™ (dexamethasone insert) 0.4mg for the treatment of ocular pain following ophthal
Southern College of Optometry’s Tips to Protect Your Eyes During the Total Eclipse
MEMPHIS, Tenn.–(BUSINESS WIRE)–A total solar eclipse will be crossing the U.S. on Aug. 21. Experts at Southern College of Optometry and American Paper Optics offer tips for safe viewing.
Global Intraocular Lens (IOLs) Market 2017-2021 – Key Vendors are Alcon, Bausch & Lomb, Carl Zeiss & Johnson & Johnson – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Intraocular Lens (IOLs) Market 2017-2021” report to their offering. The global Intraocular Lens (IOLs) market to grow at a CAGR of 4.42 % during the period 2017-202…
Second Sight Announces Market Entry into South Korea with Two Implants and Performs Second Implant in Taiwan of Argus II Retinal Prosthesis System
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today announced market entry into South Korea, implanting two patients with the Company’s Argus® II Retinal Prosthesis System (“Argus II”) in Seoul. The implants were facilitated by the country’s exclusive distribution partner, Kisantech Co., Ltd. A second patient
Global Soft Contact Lens Market 2017-2021 – Key vendors are CooperVision, Johnson & Johnson, Novartis & Valeant Pharmaceuticals – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Soft Contact Lens Market 2017-2021” report to their offering. The analysts forecast the global soft contact lens market to grow at a CAGR of 7.64% during the period…
Nightstar Raises $45 Million to Fund Development of Gene Therapies for Blinding Retinal Diseases
BOSTON & LONDON–(BUSINESS WIRE)–Nightstar Raises $45 Million to Fund Development of Gene Therapies for Blinding Retinal Diseases
Visioneering Technologies, Inc. Announces Connie Stewart as Territory Manager, Los Angeles
ATLANTA–(BUSINESS WIRE)–Connie Stewart has been named Visioneering Technologies Territory Manager for Los Angeles, where she will introduce NaturalVue(R) products.
Aerpio Announces Initiation of Patient Dosing in the TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced the initiation of patient dosing in the company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate AKB-9778 for patients with moderate to severe non-proliferative diabetic retinopathy. The TIME-2b study is a double-masked, placebo-controlled, multi-center trial that